Potential prognostic value of CSF-targeted proteomics across the Alzheimer’s disease continuum

• Published in: BMC geriatrics Vol. 24; no. 1; pp. 501 - 12
• Main Authors: Xu, Bingdong, Ling, Yitong, Liu, Leiyuan, Liu, Yujun, Lin, Yingze, Lyu, Jun, Zhang, Yusheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.06.2024; BioMed Central; BMC
• Subjects: Accuracy; Advertising executives; Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer Disease - metabolism; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Peptides - metabolism; Biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Chromatography; Cognitive ability; Cognitive Dysfunction - cerebrospinal fluid; Cognitive Dysfunction - diagnosis; Cognitive function; Cohort Studies; Dementia; Development and progression; Disease Progression; Diseases; Female; Follow-Up Studies; Health aspects; Hippocampus; Humans; Male; Mass spectrometry; Mediation; Medical prognosis; Memory; Methods; Middle Aged; Neurodegenerative diseases; Neuropsychology; Older people; Peptides; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Proteomics - methods; Scientific imaging; Software; Tau protein; tau Proteins - cerebrospinal fluid; China; Biomarkers; Prognosis; Alzheimer’s disease; Cognitive function; Proteomics
• DOI: 10.1186/s12877-024-05104-z
• ISSN: 1471-2318

Core biomarkers for Alzheimer's disease (AD), such as Aβ42 and tau, have demonstrated high prognostic accuracy but do not fully capture the complex pathophysiology of AD. In this study, our objective was to identify novel cerebrospinal fluid (CSF) biomarkers using proteomics across the entire AD continuum to predict conversion to AD and explore their involvement in AD pathogenesis. A cohort of 186 cognitively normal (CN), 127 subjective memory complaint (SMC), 79 early mild cognitive impairment (EMCI), 249 late MCI (LMCI), and 132 AD individuals was analyzed, with a follow-up period of over 3 years for non-AD participants. CSF 65 peptides, as well as hippocampal and entorhinal volumes were analyzed, and cognitive function was evaluated using the 13-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog 13). Cox proportional hazards models and mediation analysis were performed to investigate associations and causal relationships. During the follow-up, approximately one-fourth (146/580) of the non-AD participants progressed to AD. After adjusting for baseline diagnosis (CN to LMCI) and other variables, multivariable Cox regression analysis identified three peptides (VAELEDEK, VSFELFADK, and VVSSIEQK) as significant predictors of conversion to AD. Incorporating these three peptides into the initial model significantly improved the C-statistic from 0.82 to 0.85 for predicting AD conversion, surpassing the predictive ability of Aβ42 and P-tau. Moreover, hippocampal and entorhinal volumes mediated 30.3-53.8% of the association between the three peptides and ADAS-Cog 13 scores. These findings underscore the potential of these three peptides as robust prognostic biomarker candidates for AD conversion across the entire AD continuum, with a mechanism involving the mediation of hippocampal and entorhinal volumes.